Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial

Affiliations

• ¹ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: AFATHI@mgh.harvard.edu.
• ² The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ³ Servier Pharmaceuticals LLC, Boston, MA, USA.
• ⁴ Fortrea, Durham, NC, USA.
• ⁵ Istituto Scientifico Romagnolo per lo Studio e la Cera dei Tumori (IRST), IRCCS, Meldola, Italy.